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Abstract: Although recent experimental studies indicate that disc-derived cytokines, as for instance TNF, seems to be 
intimately involved in the pathophysiology of sciatica and low back pain, the clinical studies performed do not provide 
conclusive data on TNF-inhibition as a useful complement for treatment of such conditions to existing modalities. Based 
on the fact that TNF is merely one component in a complex network it was assumed that the combination of a TNF-
inhibitor and an IL-1-inhibitor could potentiate the effects in a pig model on nucleus pulposus-induced nerve conduction 
velocity reduction. The data indicated that combination of two cytokine inhibitors seems to be more efficient in reducing 
the nucleus pulposus-induced effects on nerve conduction velocity than using each inhibitor separately. This may be 
considered if future clinical trials for the treatment of sciatica and low back pain using just a single inhibitor may continue 
to demonstrate inconclusive data. 
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INTRODUCTION 
  There is accumulating experimental evidence that 
sciatica due to disc herniation and low back pain may relate 
to activation and sensitization of intraspinal nervous 
structures by disc-derived substances [1-5]. One key 
substance for inducing such irritation is Tumor Necrosis 
Factor alpha (TNF) [1, 6-8]. However, initial clinical trials 
on TNF-inhibition for treating sciatica have indicated both 
good [9-12] and less conclusive results [13-16]. Although 
TNF is considered as a “major player” in inflammatory 
events, TNF also acts through other pro-inflammatory 
cytokines such as for instance IL-1, IL-6 and IFN-gamma. 
One might therefore assume that inhibition of other 
cytokines in combination with TNF may enhance the effects 
since one would inhibit the cytokine network at multiple 
levels. A previous experimental study showed that direct 
administration of a TNF-antibody at a certain dosage into the 
nucleus pulposus before application to the cauda equina may 
only produce a partial reduction of the nucleus pulposus-
induced effects on nerve conduction velocity in a pig model 
[1]. Using this approach, it was assessed if the addition of an 
antibody towards IL-1 could potentiate this effect. 
MATERIAL AND METHODS 
  Fifteen pigs, (body weight 25-30 kg) received an 
intramuscular injection of 20 mg/kg body weight of Ketalar
® 
(ketamine 50 mg/ml, Parke-Davis, Morris Plains, New 
Jersey) and an intravenous injection of 4 mg/kg body weight 
of Hypnodil
® (methomidate chloride 50 mg/ml, AB Leo, 
Helsingborg, Sweden) and 0.1 mg/kg body weight of 
Stresnil
® (azaperon 2 mg/ml, Janssen Pharmaceutica, Beerse,  
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Belgium). Anesthesia was maintained by additional 
intravenous injections of 2 mg/kg body weight of Hypnodil
® 
and 0.05 mg/kg body weight of Stresnil
®. The pigs also 
received an intravenous injection of 0.1 mg/kg of 
StesolidNovum
® (Diazepam, Dumex, Helsingborg) after 
surgery. 
  Nucleus pulposus was harvested from the 5th lumbar disc 
through a retroperitoneal approach. Approximately 40 mg of 
the nucleus pulposus (content of one lumbar disc) was 
applied to the sacro-coccygeal cauda equina in the same pig 
through a midline incision and laminectomy of the first 
coccygeal vertebra. In 5 pigs, the nucleus pulposus was 
mixed with 100 g of an anti-TNF antibody (anti-pig 
TNF monoclonal purified antibody, Endogen, Woburn, 
MA, USA) before application [1]. In five other pigs, the 
nucleus pulposus was mixed with 100 g of an anti-IL-1 
antibody (anti-pig IL-1 monoclonal purified antibody, 
Endogen, Woburn, MA, USA), and in the remaining 5 pigs 
both 100 g of an anti-TNF antibody and 100 g of an 
anti-IL-1 antibody was mixed with the nucleus pulposus. 
  Seven days after the application, the pigs were 
reanaestetized by an intramuscular injection of 20mg/kg 
body weight of Ketalar
® and an intravenous injection of 
35mg/kg body weight of Pentothal
® (Thiopental sodium, 
Abbott lab, Chicago, IL). The pigs were ventilated on a 
respirator. Anesthesia was maintained by an intravenous 
bolus injection of 100 mg/kg body weight of Chloralose ()-
D(+)-gluco-chloralose, Merck, Darmstadt, Germany) and by 
a continuous supply of 30 mg/kg/hour of Chloralose. A 
laminectomy from the 4th sacral to the 3rd coccygeal ver-
tebra was performed. The nerve roots were covered with 
Spongostane
® (Ferrosan, Denmark). Local tissue temperature 
was continuously monitored and maintained at 37.5-38.0˚C 
by means of a heating lamp. 152    The Open Orthopaedics Journal, 2011, Volume 5  Kjell Olmarker 
  The cauda equina was stimulated by two E2 subdermal 
platinum needle electrodes (Grass Instrument Co., Quincy, 
MA) which were connected to a Grass SD9 stimulator 
(Grass Instrument Co., Quincy, MA) and gently placed 
intermittently on the cauda equina first 10 mm cranial and 
then 10 mm caudal to the exposed area. To ensure that only 
impulses from exposed nerve fibers were registered, the 
nerve root that exited from the spinal canal between the two 
stimulation sites were cut. An EMG was registered by two 
subdermal platinum needle electrodes, which were placed 
into the paraspinal muscles in the tail approximately 10 mm 
apart. This procedure is reproducible and represents a 
functional measurement of the motor nerve fibers of the 
cauda equina nerve roots. The EMG was visualized using a 
Macintosh IIci computer provided with Superscope software 
and MacAdios II A/D converter (GW Instruments, 
Sommerville, MA). The separation distance between the first 
peaks of the EMG from the two recordings was determined 
and the separation distance between the two stimulation sites 
on the cauda equina was measured with calipers. The nerve 
conduction velocity between the two stimulation sites could 
thus be calculated from these two measurements. 
  The person performing the neurophysiologic analyzes 
was unaware of the experimental protocol for the individual 
animal. For comparison, data from a previous study of the 
effects of application of retroperitoneal fat and autologous 
nucleus pulposus were included [17]. After finishing the 
complete study the data were arranged in the three 
experimental groups and statistical differences between each 
group and the group with nucleus pulposus application 
without treatment was assessed by ANOVA and Fishers 
post-hos test. 
  The local animal research ethics committee approved the 
experimental protocol for this experiment. 
RESULTS 
  The average nerve conduction velocity for the five 
groups is displayed in Fig. (1). In a previous study, baseline 
nerve conduction velocity (fat) was 76 m/s and application 
of autologous nucleus pulposus induced a reduction of the 
conduction velocity to 45 m/s [17]. Application of an anti-
IL-1-antibody to the nucleus pulposus did not seem to 
reduce the effects of the nucleus pulposus (NP-IL-1; 
p=0,8946). Addition of an anti-TNF antibody was more 
efficient than the IL-1-antibody but only produced a partial 
reduction of the nucleus pulposus effects (NP-TNF; 
p=0,0788. Most efficient in blocking the nucleus pulposus 
induced reduction in nerve conduction velocity was the 
combined action of the anti-TNF and the anti-IL-1-antibody 
(NP-IL-1+TNF; p=0,0007). The data from the IL1+TNF 
group was statistically different to both the TNF group 
(p=0,0442) and the IL-1 group (p=0,0010). 
DISCUSSION 
  It the present study it was evident that the combination of 
a TNF-inhibitor and a IL-1-inhibitor was more efficient in 
reducing the nucleus pulposus-induced reduction in nerve 
conduction velocity in a pig model than using each inhibitor 
separately. 
  From recent experimental studies is has become 
increasingly clear that cytokines from the nucleus pulposus 
may play a role in nerve dysfunction and pain production 
when the intra spinal nerve tissue is exposed to nucleus 
pulposus material [1-5]. Most attention has been drawn to 
TNF but there are also other substances that may be involved 
in these pathophysiologic events such as for instance IL-1, 
IL-6 and IFN-gamma [1, 6-8]. Clinical investigations on 
TNF-inhibition for the reduction of sciatic and low back pain 
have displayed both good [9-12] and less conclusive [13-16] 
results. Since TNF is just one substance in a network of 
synergistic molecules one may suspect that one reason for 
the absence of clinically detectable efficacy might be 
overcome if combining inhibition of several inhibitors. 
  To assess this hypothesis a previously published pig 
model, in which TNF-inhibition only displayed a partial 
reduction of the nucleus pulposus-induced effects, was used 
[1]. In that study a pig anti-TNF antibody was mixed with 
the autologous nucleus pulposus before application onto the 
cauda equina. The anti-TNF antibody reduced the nucleus 
pulposus-induced reduction of nerve conduction velocity 
from 45 m/s (nucleus pulposus) to 64 m/s, which should be 
compared to 76 m/s following application of fat tissue used 
 
Fig. (1). Nerve conduction velocity 7 days after application (±SD) of fat (negative control) [17], nucleus pulposus (positive control) [17] and 
nucleus pulposus mixed with antibodies towards IL-1(IL-1) and TNF. Statistically significant difference for these three latter groups 
compared to nucleus pulposus application was only seen in the IL-1+TNF group. Combination of Two Cytokine Inhibitors  The Open Orthopaedics Journal, 2011, Volume 5    153 
as negative control. In that study, nerve conduction velocity 
recording were performed 3 days following nucleus pulpous 
application, but in the present study a 7-day exposure time 
was selected. 
  The study showed that also after 7 days there was only a 
partial reduction of the nucleus pulposus-induced reduction 
of nerve conduction velocity when an anti-TNF antibody in 
the same dosage as in the previous publication was mixed 
with the nucleus pulposus (Fig. 1). Mixing the nucleus 
pulposus with the same amount of an anti-IL-1-antibody 
did not seem to reduce the nucleus pulposus-induced 
reduction of nerve conduction velocity, whereas combination 
of both antibodies produced a seemingly complete reduction. 
The dosages of the two antibodies were chosen without any 
previous pilot experiments but since they separately only 
induced incomplete reduction of the nucleus pulposus-
induced effects they were regarded to be adequate for the 
intended purpose. 
CONCLUSION 
  Combination of two cytokine inhibitors seems to be more 
efficient in reducing the nucleus pulposus-induced effects on 
nerve conduction velocity than using each inhibitor 
separately This may be considered if clinical trials for the 
treatment of sciatica and low back pain using just a single 
inhibitor may demonstrate inconclusive data. 
ABBREVIATIONS 
TNF  =  Tumor Necrosis Factor (alpha) 
IL-1 =  Interleukin  1 
IL-1  =  Interleukin 1 beta 
IL-6 =  Interleukin-6 
IFN-gamma = Interferon-gamma 
EMG =  Electromyogram 
ANOVA  =  Analysis of variance 
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